Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients

Nora Angyal, Erzsebet Zsofia Horvath, Zsanett Tarnok, Mara J. Richman, Emese Bognar, K. Lakatos, M. Sasvári, Z. Nemoda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: Methylphenidate (MPH) is the most frequently prescribed drug in Attention Deficit Hyperactivity Disorder (ADHD). Hitherto mostly the dopamine transporter gene has been studied in MPH-response and only a few studies analyzed the norepinephrine transporter (NET, SLC6A2) gene, although MPH is a potent inhibitor of both dopamine and norepinephrine transporters. We aimed to analyze this monoamine transporter gene in relation to ADHD per se and MPH-response in particular to gain further knowledge in ADHD pharmacogenetics using a Caucasian sample. Methods: Six single nucleotide polymorphisms (rs28386840, rs2242446, rs3785143, rs3785157, rs5569, rs7194256 SNP) were studied across the NET gene in 163 ADHD children (age: 9.3 ± 2.6; 86.5% male) using ADHD-RS hyperactivity-impulsivity and inattention scales. For case-control analysis 486 control subjects were also genotyped. At the MPH-response analysis responders had minimum 25% decrease of ADHD-RS total score after 2 months of treatment, and chi-square test compared 90 responders and 32 non-responders, whereas ANOVA was used to assess symptom improvement after the first month among the 122 ADHD patients. Results: The classical case-control analysis did not yield any association with ADHD diagnosis, which was supported by meta-analysis conducted on the available genetic data (combining previously published and the present studies). On the other hand, the intronic rs3785143 showed nominal association with inattention symptoms (p = 0.01). The haplotype analysis supported this association, and indicated the importance of the first haploblock encompassing the intronic and 2 promoter SNPs. With MPH-response only the promoter rs28386840 showed nominal association: Those with at least one T-allele were overrepresented in the responder group (42% vs 19%, p = 0.08), and they had better improvement on the hyperactivity-impulsivity scale compared to the AA genotype (p = 0.04). Conclusion: Although none of our single SNP findings remained significant after correcting for multiple testing, our results from the MPH-response analysis indicate the potential importance of promoter variants in the NET gene.

Original languageEnglish
Pages (from-to)122-128
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume84
DOIs
Publication statusPublished - Jun 8 2018

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
Methylphenidate
Attention Deficit Disorder with Hyperactivity
Single Nucleotide Polymorphism
Dopamine Plasma Membrane Transport Proteins
Impulsive Behavior
Genes
Pharmacogenetics
Chi-Square Distribution
Haplotypes
Meta-Analysis
Analysis of Variance
Alleles
Genotype

Keywords

  • ADHD (attention deficit hyperactivity disorder)
  • Methylphenidate
  • Norepinephrine/noradrenaline transporter, SLC6A2 (solute carrier family 6, member 2)
  • Pharmacogenetics
  • Promoter polymorphism

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients. / Angyal, Nora; Horvath, Erzsebet Zsofia; Tarnok, Zsanett; Richman, Mara J.; Bognar, Emese; Lakatos, K.; Sasvári, M.; Nemoda, Z.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 84, 08.06.2018, p. 122-128.

Research output: Contribution to journalArticle

@article{b5c1ebbbaf3b4db189edfbd2dad9ed70,
title = "Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients",
abstract = "Aims: Methylphenidate (MPH) is the most frequently prescribed drug in Attention Deficit Hyperactivity Disorder (ADHD). Hitherto mostly the dopamine transporter gene has been studied in MPH-response and only a few studies analyzed the norepinephrine transporter (NET, SLC6A2) gene, although MPH is a potent inhibitor of both dopamine and norepinephrine transporters. We aimed to analyze this monoamine transporter gene in relation to ADHD per se and MPH-response in particular to gain further knowledge in ADHD pharmacogenetics using a Caucasian sample. Methods: Six single nucleotide polymorphisms (rs28386840, rs2242446, rs3785143, rs3785157, rs5569, rs7194256 SNP) were studied across the NET gene in 163 ADHD children (age: 9.3 ± 2.6; 86.5{\%} male) using ADHD-RS hyperactivity-impulsivity and inattention scales. For case-control analysis 486 control subjects were also genotyped. At the MPH-response analysis responders had minimum 25{\%} decrease of ADHD-RS total score after 2 months of treatment, and chi-square test compared 90 responders and 32 non-responders, whereas ANOVA was used to assess symptom improvement after the first month among the 122 ADHD patients. Results: The classical case-control analysis did not yield any association with ADHD diagnosis, which was supported by meta-analysis conducted on the available genetic data (combining previously published and the present studies). On the other hand, the intronic rs3785143 showed nominal association with inattention symptoms (p = 0.01). The haplotype analysis supported this association, and indicated the importance of the first haploblock encompassing the intronic and 2 promoter SNPs. With MPH-response only the promoter rs28386840 showed nominal association: Those with at least one T-allele were overrepresented in the responder group (42{\%} vs 19{\%}, p = 0.08), and they had better improvement on the hyperactivity-impulsivity scale compared to the AA genotype (p = 0.04). Conclusion: Although none of our single SNP findings remained significant after correcting for multiple testing, our results from the MPH-response analysis indicate the potential importance of promoter variants in the NET gene.",
keywords = "ADHD (attention deficit hyperactivity disorder), Methylphenidate, Norepinephrine/noradrenaline transporter, SLC6A2 (solute carrier family 6, member 2), Pharmacogenetics, Promoter polymorphism",
author = "Nora Angyal and Horvath, {Erzsebet Zsofia} and Zsanett Tarnok and Richman, {Mara J.} and Emese Bognar and K. Lakatos and M. Sasv{\'a}ri and Z. Nemoda",
year = "2018",
month = "6",
day = "8",
doi = "10.1016/j.pnpbp.2018.01.013",
language = "English",
volume = "84",
pages = "122--128",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients

AU - Angyal, Nora

AU - Horvath, Erzsebet Zsofia

AU - Tarnok, Zsanett

AU - Richman, Mara J.

AU - Bognar, Emese

AU - Lakatos, K.

AU - Sasvári, M.

AU - Nemoda, Z.

PY - 2018/6/8

Y1 - 2018/6/8

N2 - Aims: Methylphenidate (MPH) is the most frequently prescribed drug in Attention Deficit Hyperactivity Disorder (ADHD). Hitherto mostly the dopamine transporter gene has been studied in MPH-response and only a few studies analyzed the norepinephrine transporter (NET, SLC6A2) gene, although MPH is a potent inhibitor of both dopamine and norepinephrine transporters. We aimed to analyze this monoamine transporter gene in relation to ADHD per se and MPH-response in particular to gain further knowledge in ADHD pharmacogenetics using a Caucasian sample. Methods: Six single nucleotide polymorphisms (rs28386840, rs2242446, rs3785143, rs3785157, rs5569, rs7194256 SNP) were studied across the NET gene in 163 ADHD children (age: 9.3 ± 2.6; 86.5% male) using ADHD-RS hyperactivity-impulsivity and inattention scales. For case-control analysis 486 control subjects were also genotyped. At the MPH-response analysis responders had minimum 25% decrease of ADHD-RS total score after 2 months of treatment, and chi-square test compared 90 responders and 32 non-responders, whereas ANOVA was used to assess symptom improvement after the first month among the 122 ADHD patients. Results: The classical case-control analysis did not yield any association with ADHD diagnosis, which was supported by meta-analysis conducted on the available genetic data (combining previously published and the present studies). On the other hand, the intronic rs3785143 showed nominal association with inattention symptoms (p = 0.01). The haplotype analysis supported this association, and indicated the importance of the first haploblock encompassing the intronic and 2 promoter SNPs. With MPH-response only the promoter rs28386840 showed nominal association: Those with at least one T-allele were overrepresented in the responder group (42% vs 19%, p = 0.08), and they had better improvement on the hyperactivity-impulsivity scale compared to the AA genotype (p = 0.04). Conclusion: Although none of our single SNP findings remained significant after correcting for multiple testing, our results from the MPH-response analysis indicate the potential importance of promoter variants in the NET gene.

AB - Aims: Methylphenidate (MPH) is the most frequently prescribed drug in Attention Deficit Hyperactivity Disorder (ADHD). Hitherto mostly the dopamine transporter gene has been studied in MPH-response and only a few studies analyzed the norepinephrine transporter (NET, SLC6A2) gene, although MPH is a potent inhibitor of both dopamine and norepinephrine transporters. We aimed to analyze this monoamine transporter gene in relation to ADHD per se and MPH-response in particular to gain further knowledge in ADHD pharmacogenetics using a Caucasian sample. Methods: Six single nucleotide polymorphisms (rs28386840, rs2242446, rs3785143, rs3785157, rs5569, rs7194256 SNP) were studied across the NET gene in 163 ADHD children (age: 9.3 ± 2.6; 86.5% male) using ADHD-RS hyperactivity-impulsivity and inattention scales. For case-control analysis 486 control subjects were also genotyped. At the MPH-response analysis responders had minimum 25% decrease of ADHD-RS total score after 2 months of treatment, and chi-square test compared 90 responders and 32 non-responders, whereas ANOVA was used to assess symptom improvement after the first month among the 122 ADHD patients. Results: The classical case-control analysis did not yield any association with ADHD diagnosis, which was supported by meta-analysis conducted on the available genetic data (combining previously published and the present studies). On the other hand, the intronic rs3785143 showed nominal association with inattention symptoms (p = 0.01). The haplotype analysis supported this association, and indicated the importance of the first haploblock encompassing the intronic and 2 promoter SNPs. With MPH-response only the promoter rs28386840 showed nominal association: Those with at least one T-allele were overrepresented in the responder group (42% vs 19%, p = 0.08), and they had better improvement on the hyperactivity-impulsivity scale compared to the AA genotype (p = 0.04). Conclusion: Although none of our single SNP findings remained significant after correcting for multiple testing, our results from the MPH-response analysis indicate the potential importance of promoter variants in the NET gene.

KW - ADHD (attention deficit hyperactivity disorder)

KW - Methylphenidate

KW - Norepinephrine/noradrenaline transporter, SLC6A2 (solute carrier family 6, member 2)

KW - Pharmacogenetics

KW - Promoter polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85042180765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042180765&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2018.01.013

DO - 10.1016/j.pnpbp.2018.01.013

M3 - Article

C2 - 29374517

AN - SCOPUS:85042180765

VL - 84

SP - 122

EP - 128

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

ER -